Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Boehringer Ingelheim. (4/24/14). "Press Release: Hydra Biosciences and Boehringer Ingelheim Announce Worldwide Collaboration to Develop Small-molecule Inhibitors for the Treatment of Central Nervous System Diseases and Disorders". Cambridge, MA & Ingelhe

Region Region ALL
Organisations Organisation Boehringer Ingelheim (Group)
  Organisation 2 Hydra Biosciences Inc.
Products Product TRPC4/5 inhibitor
  Product 2 small-molecule drug
Index term Index term Boehringer–Hydra Biosciences: CNS drugs, 201404– collab ww r+d small-molecule TRPC4/5 inhibitors for CNS diseases
Persons Person Herndon, Russell (Hydra Biosciences 201404 CEO)
  Person 2 Sommer, Bernd (Boehringer Ingelheim 201312 Head of Neuroscience Research)
     


Hydra Biosciences, Inc., a leader in the field of Transient Receptor Potential (TRP) channel modulation, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced today that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders.

"We are extremely pleased to be working with Boehringer Ingelheim, a company that shares our dedication for developing innovative products that improve patient's lives. The combination of Hydra's unique understanding of TRP channels and BI's proven research, development and commercialization capabilities provides an excellent opportunity to maximize the potential of these novel targets," said Russell Herndon, President and CEO of Hydra Biosciences.

"We are very excited to collaborate with Hydra Biosciences and to be able to build on their significant expertise in the field of TRP channels in our endeavors to provide the numerous patients suffering from CNS disorders with new treatments that offer meaningful therapeutic improvement", said Bernd Sommer, VP of Neuroscience Research at Boehringer Ingelheim.

Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an upfront payment, additional research funding, and is eligible to receive milestone payments and tiered royalty payments on future product sales.


About Hydra Biosciences

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels. Hydra Biosciences' proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: www.hydrabiosciences.com.


About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com


Media contact

Boehringer Ingelheim
Media & PR
Dr Reinhard Malin
Binger Strasse 173
55216 Ingelheim am Rhein

GERMANY
Phone + 49 - 6132 - 77 90815
Fax + 49 - 6132 - 77 6601


BOEHRINGER INGELHEIM CONTACT (US ENQUIRIES):
Kate O'Connor
Executive Director, Public Relations
Tel.: 203 791 6250
kate.oconnor@boehringer-ingelheim.com


HYDRA BIOSCIENCES CONTACT:

Corporate:
Russell Herndon, President and CEO
617-494-5230 x3352

Media:
Aurora Krause, LaVoie Group
617-374-8800 x105
AKrause@lavoiehealthscience.com

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top